These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 27414740)
1. Use of Paliperidone Palmitate Throughout a Schizoaffective Disorder Patient's Gestation Period. Zamora Rodríguez FJ; Benítez Vega C; Sánchez-Waisen Hernández MR; Guisado Macías JA; Vaz Leal FJ Pharmacopsychiatry; 2017 Jan; 50(1):38-40. PubMed ID: 27414740 [No Abstract] [Full Text] [Related]
2. [Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder]. Bellantuono C; Santone G Riv Psichiatr; 2012; 47(1):5-20. PubMed ID: 22358213 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study. Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570 [TBL] [Abstract][Full Text] [Related]
4. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation. Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder. Legrand G; Andrianarisoa M; Mauvieux J; Jalenques I J Clin Psychopharmacol; 2014 Oct; 34(5):652-3. PubMed ID: 25006816 [No Abstract] [Full Text] [Related]
6. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery. Williams W; McKinney C; Martinez L; Benson C J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481 [TBL] [Abstract][Full Text] [Related]
7. Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report. Matsuura H; Kimoto S; Harada I; Naemura S; Yamamuro K; Kishimoto T BMC Psychiatry; 2016 May; 16():161. PubMed ID: 27229149 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder. Macaluso M; Oliver H; Sohail Z Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):871-879. PubMed ID: 28675307 [TBL] [Abstract][Full Text] [Related]
9. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Joshi K; Lin J; Lingohr-Smith M; Fu DJ J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457 [TBL] [Abstract][Full Text] [Related]
11. The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate. Omer HM; Thompson AD Aust N Z J Psychiatry; 2018 May; 52(5):496-497. PubMed ID: 29338294 [No Abstract] [Full Text] [Related]
12. Oral Facial Dystonia (Meige or Brueghel Syndrome) Induced by Paliperidone Palmitate. Marques JG Prim Care Companion CNS Disord; 2017 Jan; 19(1):. PubMed ID: 28129491 [No Abstract] [Full Text] [Related]
13. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685 [TBL] [Abstract][Full Text] [Related]
14. Paliperidone Palmitate-Associated Severe Refractory Tardive Dyskinesia With Tardive Dystonia: Management and Six-Months Follow-Up. Singh S; Gupta A; Kuppili PP; Pattanayak RD; Khandelwal SK J Clin Psychopharmacol; 2016 Aug; 36(4):391-3. PubMed ID: 27269958 [No Abstract] [Full Text] [Related]
15. De novo cost-utility analysis of oral paliperidone in the treatment of schizoaffective disorder. Přibylová L; Kolek M; Veselá Š; Duba J; Šlesinger J; Dolečková J J Psychiatr Res; 2015 Nov; 70():33-7. PubMed ID: 26424421 [TBL] [Abstract][Full Text] [Related]
16. Paliperidone-Induced Hyponatremia. Tibrewal P; Dhillon R; Sharma J; Bastiampillai T Prim Care Companion CNS Disord; 2017 Jul; 19(4):. PubMed ID: 28767207 [No Abstract] [Full Text] [Related]
17. Paliperidone for the treatment of schizoaffective disorder. Alphs L; Fu DJ; Turkoz I Expert Opin Pharmacother; 2016; 17(6):871-83. PubMed ID: 26934062 [TBL] [Abstract][Full Text] [Related]